the limited number of approved and effective pharmacotherapies that currently exist for alcohol dependence. One promising avenue to ameliorate the treatment gap would be to provide many novel pharmacotherapies that have diverse mechanisms of action that are well-tolerated and effective. This strategy has merit because the arrival of many novel pharmacotherapies for depression over the last 30 years, for example, helped catalyze a transformation in the way depression is perceived and treated. In this regard, the power of high-throughput discovery based methods from disciplines such as genomics can be used to identify many new drug targets (Kingsmore et al., 2008; Sanseau et al., 2012).
